Роль антиаритмических препаратов IС класса в моно- и комбинированной фармакотерапии наджелудочковых нарушений ритма сердца

1. Miller JM, Zipes DP. Therapy for cardiac arrhythmias. In E.Braunwald, P.Libby, R.Bonow et al. Heart Disease. Saunders Company 2008; p. 779–826.
2. Guidelines for de management of atrial fibrillation. Eur Heart J 2010; 31: 2369–429.
3. Бунин Ю.А., Татарский Б.А. Дронедарон: обманутые надежды. Сердце. 2012; 11 (1): 27–9.
4. Capucci A, Aschieri D. Antiarrhythmic drug therapy: what is certain and what is to come. Eur Heart J (Suppl. H) 2003; 5: H8–H18.
5. Bellandi F, Simonetti I, Leoncini M et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001; 88: 640–5.
6. Prichett EL, Page RL, Carlson M et al. Efficacy and safety of sustained-release propafenone for patients with atrial fibrillation. Am J Cardiol 2003; 92: 941–6.
7. Бунин Ю.А., Федякина Л.Ф. Эффективность моно- и комбинированной антиаритмической фармакотерапии пропафеноном в профилактике частых рецидивов пароксизмальной фибрилляции предсердий. Рос. кардиол. журн. 2007; 3: 62–5.
8. Бунин Ю.А., Денисов О.Н., Федякина Л.Ф. Профилактическая антиаритмическая фармакотерапия частых пароксизмов фибрилляции предсердий и некоторых видов наджелудочковых тахикардий пропафеноном в сравнении с плацебо. Рос. кардиол. журн. 2010; 5: 77–82.
9. АСС/АНА/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text. Europace 2006; 8: 651–745.
10. Бунин Ю.А., Федякина Л.Ф. Комбинированная профилактическая антиаритмическая фармакотерапия фибрилляции и трепетания предсердий. Рос. кардиол. журн. 2006; 6: 35–45.
11. Chevalier P, Durand-Dubief A, Burri H. Amiodarone versus placebo and class IC drugs cardioversion of recent-onset atrial fibrillation: a meta-analysis. JACC 2003; 41: 255–61.
12. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37: 542–7.
13. Bunin Yu, Anfalova L. Efficacy of propafenone as single oral loading dose in pharmacology converting recent-onset atrial fibrillation and atrial flutter. Europace 2005; 7 (Suppl. 1): 121–2.
14. Saoudi N, Cosio F, Waldo A et al. A classification on atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases. Eur Heart J 2001; 22 (14): 1162–82.
15. ACC/AHA/ESC guidelines for management of patients with supraventricular arrhythmias-executive summary. Eur Heart J 2003; 24: 1857–97.
16. Berns E, Rinkenberger RL, Jeang MK et al. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987; 59: 1337–41.
17. Lucet V, Do ND, Fidelle J. Anti-arrhythmia efficacy of propafenone in children. Arch Mal Coeur Vaiss 1987; 80: 1385–93.
18. Colloridi V, Perri C, Ventriglia F et al. Oral sotalol in pediatric atrial ectopic tachycardia. Am Heart J 1992; 123: 254–6.
19. Guccione P, Paul T, Garson A. Long-term follow-up of amiodarone therapy in the young. J Am Coll Cardiol 1990; 15: 1118–24.
20. Prager NA, Cox JL, Lindsay BD et al. Long-term effectiveness of surgical treatment of ectopic atrial tachycardia. J Am Coll Cardiol 1993; 22: 85–92.
21. UK propafenone PSVT study group. A randomized placebo-controlled trail of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995; 92: 2550–7.
22. Vignati G, Mauri L, Figini A. The use propafenone in the treatment of tachyarrhythmias in children. Eur Heart J 1993; 14: 546–50.
23. Kuck KH, Kunze KP, Schluter M et al. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Am J Cardiol 1988; 62: 37L–44L.
24. Flammang D, Coumel P. Supraventricular tachycardia with re-entry in the sinus node or atria. In J.Kastor (ed.). Arrhythmias. Philadelphia: W.B.Sounders Company 1994; p. 297–309.
25. Roberts-Thomson KC, Kistler PM, Kalman JM. Atrial tachycardia: mechanisms, diagnosis and management. Curr Probl Cardiol 2005; 30: 529–73.
26. Бунин Ю.А. Диагностика и лечение тахиаритмий сердца. М.: Медпрактика, 2011.
27. Creamer JE, Nathan AW, Camm AJ. Successful treatment of atrial tachycardias with flecainide acetate. Br Heart J 1985; 53: 164–6.
28. Reimer A, Paul T, Kallfelz H-C. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmia. Am J Cardiol 1991; 68: 741–4.
29. Bigger JT, Goldreyer BN. The mechanism of paroxysmal supraventricular tachycardia in man. Circulation 1970; 42: 673–88.
30. Atiga WA, Calkins H. Catheter ablation of supraventricular tachycardias. In L.Ganz, E.Braunwald (eds.). Management of cardiac arrhythmias. Hymana Press 2002; p. 51–73.
31. Olgin JE, Zipes DP. Specific arrhythmias: diagnosis and treatment. In E.Braumwald, D.Zipes, P.Libby, R.Bonow (eds.). Heart disease. Saunders Company 2005; p. 803–63.
32. Ferguson JD, Di Marco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation 2003; 107: 1096–9.
33. Dorian P, Naccarelli GV, Coumel P et al. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. Am J Cardiol 1996; 77: 89A–95A.
34. Мухаммед Нурул Ислам. Сравнительная эффективность финоптина, этмозина и этацизина в профилактическом лечении пароксизмальных наджелудочковых тахикардий. Автореф. дис. ... канд. мед. наук. М., 1987.
35. Алиханов Г.Н. Изучение антиаритмической активности аллапинина и оценка его сравнительной эффективности при различных формах нарушений ритма сердца. Автореф. дис. ... канд. мед. наук. М., 1987.
36. Helmy I, Scheinman MM, Herre JM et al. Electrophysiologic effects of isoproterenol in patients with atrioventricular reentrant tachycardia treated with flecainide. J Am Coll Cardiol 1990; 16: 1649–55.
37. Gillette PS, Case CL, Kastor JA. Junctional ectopic tachycardia. In J.Kastor (ed.). Arrhythmias Philadelphia: W.B. Saunders Company 1994; p. 218–24.
38. Paul T et al. Efficacy and safety propafenone in congenital junctional ectopic tachycardia. J Am Coll Cardiol 1992; 20: 911–4.
39. Villain E, Vetter VL, Garsia JM et al. Evolving concepts in the management of congenital junctional ectopic tachycardia. 
A multicenter study. Circulation 1990; 81: 1544–9.
40. Maragnes P, Fournier A, Davignon A. Usefulness of oral sotalol for the treatment of junctional ectopic tachycardia. Int J Cardiol 1992; 35: 165–7.

Ю.А.Бунин 

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФ, Москва